Durr-Fillauer bidding war
Bergen Brunswig's request for an injunction forcing Durr-Fillauer to provide all the information given to Cardinal as part of the latter two companies' "definitive" merger agreement will be considered by Delaware chancery court on Aug. 6. Durr told Bergen Brunswig in a July 24 letter that "it would not be in the best interests of our shareholders to provide Bergen Brunswig, a major competitor of Durr- Fillauer, with access to confidential and sensitive information," However, Durr added that "there is no impediment to [Bergen] making a higher offer".
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth